An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades

ABSTRACT SF162 is a primary (PR), non-syncytium-inducing, macrophagetropic human immunodeficiency virus type 1 (HIV-1) clade B isolate which is resistant to antibody-mediated neutralization. Deletion of the first or second hypervariable envelope gp120 region (V1 or V2 loop, respectively) of this virus does not abrogate its ability to replicate in peripheral blood mononuclear cells and primary macrophages, nor does it alter its coreceptor usage profile. The mutant virus with the V1 loop deletion, SF162ΔV1, remains as resistant to antibody-mediated neutralization as the wild-type virus SF162. In contrast, the mutant virus with the V2 loop deletion, SF162ΔV2, exhibits enhanced susceptibility to neutralization by certain monoclonal antibodies whose epitopes are located within the CD4-binding site and conserved regions of gp120. More importantly, SF162ΔV2 is now up to 170-fold more susceptible to neutralization than SF162 by sera collected from patients infected with clade B HIV-1 isolates. In addition, it becomes susceptible to neutralization by sera collected from patients infected with clade A, C, D, E, and F HIV-1 isolates. These findings suggest that the V2, but not the V1, loop of SF162 shields an as yet unidentified region of the HIV envelope rich in neutralization epitopes and that the overall structure of this region appears to be conserved among clade B, C, D, E, and F HIV-1 PR isolates.

[1]  L. Stamatatos,et al.  Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. , 1998, AIDS research and human retroviruses.

[2]  J. Sodroski,et al.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.

[3]  D R Burton,et al.  Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.

[4]  A. Trkola,et al.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.

[5]  L. Stamatatos,et al.  Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. , 1997, Virology.

[6]  P. Kaleebu,et al.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization , 1996, Journal of virology.

[7]  S. Zolla-Pazner,et al.  Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. , 1996, Molecular immunology.

[8]  Q. Sattentau,et al.  Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation , 1996, The Journal of experimental medicine.

[9]  B. Korber,et al.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.

[10]  J. Moore,et al.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement , 1996, Journal of virology.

[11]  L. Stamatatos,et al.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding , 1995, Journal of virology.

[12]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[13]  Ying Sun,et al.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates , 1995, Journal of virology.

[14]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[15]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[16]  D R Burton,et al.  Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. , 1995, Journal of immunology.

[17]  M. Schutten,et al.  Enhancement of Infectivity of a Non‐Syncytium Inducing HIV‐1 by sCD4 and by Human Antibodies that Neutralize Syncytium Inducing HIV‐1 , 1995, Scandinavian journal of immunology.

[18]  H. Schuitemaker,et al.  Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera , 1995, Journal of virology.

[19]  J. Sodroski,et al.  Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.

[20]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[21]  P. Berman,et al.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.

[22]  L. Stamatatos,et al.  Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1 , 1994, Journal of virology.

[23]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[24]  S. Zolla-Pazner,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies , 1994, Journal of virology.

[25]  C. Hanson,et al.  Measuring vaccine-induced HIV neutralization: report of a workshop. , 1994, AIDS research and human retroviruses.

[26]  L. Sawyer,et al.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated , 1994, Journal of virology.

[27]  N. Haigwood,et al.  V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Q. Sattentau,et al.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.

[29]  Q. Sattentau,et al.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.

[30]  J. Sodroski,et al.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.

[31]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[32]  J. Levy,et al.  Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4 , 1993, Journal of virology.

[33]  S. Zolla-Pazner,et al.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. , 1993, Journal of immunology.

[34]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[35]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[36]  S. Zolla-Pazner,et al.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro , 1991, Journal of virology.

[37]  C. Cheng‐Mayer,et al.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene , 1991, Nature.

[38]  C. Cheng‐Mayer,et al.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation , 1990, Journal of virology.

[39]  C. Cheng‐Mayer,et al.  Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Levy,et al.  The FC and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. , 1989, Disease markers.

[41]  H. Mitsuya,et al.  Designing CD4 immunoadhesins for AIDS therapy , 1989, Nature.

[42]  F. Ennis,et al.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. , 1988, Science.

[43]  D. Dormont,et al.  ANTIBODY-DEPENDENT ENHANCEMENT OF HIV INFECTION , 1988, The Lancet.

[44]  D. Montefiori,et al.  ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION , 1988, The Lancet.

[45]  C. Cheng‐Mayer,et al.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[47]  Suzanne Willey Antibody-dependent enhancement of HIV infection. , 1988, Lancet.